David Perrin

This inventor holds 7 USPTO granted patents and 2 published patent applications, plus 4 CIPO patents and 5 EPO patents. Top assignees: Sidel Participations, Bioprojet. Active years: 2011-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Perrin. Retrieved from https://idiyas.com/inventor/david-perrin-p9u37q3o

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 2)

% Patents Active = 71.4

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 3)

Average Co-Inventor Count = 3.3

ph-index = 3

Forward Citations = 24(Granted Patents)

Location History:

Octeville sur Mer, FR (2011 - 2014)
Gévezé, FR (2021 - 2024)

Company Filing History:

Years Active: 2011-2024

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12059416 - Combinations of a H3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof (2024-08-13),

2. 11229632 - Combinations of a H3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof (2022-01-25),

3. 10952987 - Combination of adrenalin with an antidepressant for use in the treatment of shocks (2021-03-23),

4. 8770392 - Width-adjusting device for conveyor corridor(s) (2014-07-08),

5. 8668073 - Multipath conveyor installation (2014-03-11),

6. 8459444 - Conveying equipment including at least one curved corridor (2013-06-11),

7. 7926648 - Guide(s) mounted on a conveyor (2011-04-19),

Title: The Innovative Contributions of David Perrin

Introduction

David Perrin is a notable inventor based in Octeville-sur-Mer, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel combinations of medications. With a total of seven patents to his name, Perrin's work focuses on enhancing therapeutic efficacy through innovative drug combinations.

Latest Patents

Among his latest patents are two significant inventions: "Combinations of a H3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof." This invention discloses combinations of a H3 antagonist and an antidepressant, which exhibit a synergistic wake-promoting activity. The second patent, also titled "Combinations of a H3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof," relates to similar combinations that enhance wakefulness and therapeutic outcomes.

Career Highlights

David Perrin has worked with prominent companies in the pharmaceutical industry, including Sidel Participations and Bioprojet. His experience in these organizations has allowed him to develop and refine his innovative ideas, contributing to advancements in medication and treatment options.

Collaborations

Throughout his career, Perrin has collaborated with esteemed colleagues such as Zmaj Petrovic and Xavier Ligneau. These partnerships have fostered a creative environment that has led to the successful development of his patented inventions.

Conclusion

David Perrin's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to improving therapeutic practices. His work continues to influence the industry and offers promising advancements in medication efficacy.

Profile summary based on public USPTO records.